ESMO Immuno-Oncology Congress 2021

Andrew J.S. Furness

Biomarkers for immunotherapy: where are we?

The future is in the hands of tools built on combinations of biomarkers as no single biomarker is likely to reflect the complexity of the tumour microenvironment or account for tumour evolution

By Andrew J.S. Furness
DR @ Congress

Developing immunotherapies for mesothelioma 

Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation

  • Alessandra Curioni Fontecedro

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.